BRIGHTCOVE
25.6.2020 15:12:07 CEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, today announced Brightcove Virtual Event Experiences , a solution that allows organizations to deliver high-quality virtual events featuring bold, interactive experiences. Responding to a crucial market need, Brightcove Virtual Event Experiences enables organizations to host events with market-leading video technology to engage with audiences securely and reliably around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005507/en/
The adoption of video communications in enterprise organizations is growing at a rapid pace. According to the recent Brightcove Global Video Index , in the first quarter of 2020, video views among enterprise companies increased by 91% year over year, with preliminary year-over-year data from April and May showing viewing increases of nearly 80% and 54%, respectively. Along with this adoption, many in-person events and meetings are moving to online video. With no timetable for the return of large-scale, in-person conferences and events, marketing and event professionals are looking for an in-person alternative, and they are turning to Brightcove for guidance. Recently, Brightcove technology has helped power critical B2B, B2C, and arts/entertainment events, helping organizations scale quickly, easily, and securely while reaching new audiences across the globe, including:
- ServiceNow Knowledge 2020
- DocuSign MomentumLive
- Talkdesk® Opentalk 2020 Virtual
- NAB Show Express with over 40,000 industry professionals accessing the event since its launch
- The Dropkick Murphys’ Streaming Outta Fenway concert joined by Bruce Springsteen with over 9 million live and on-demand views to date, raising over $700,000 for charity
- The Metropolitan Opera's At Home Gala, with more than 40 artists participating from around the world, was watched by more than 750,000 people
The need to engage with customers and prospects is as critical as ever, and organizations expect to deliver innovative and measurable experiences for their audiences in order to maintain communication and engagement. The Brightcove Virtual Events Experience solution empowers companies to take immediate action to ensure that their essential in-person events can continue virtually.
Features include:
- Branding and User Experience: Control the viewer’s experience and surrounding content by hosting on Brightcove.
- Increased Value for Sponsors: Demonstrate value to sponsors and exhibitors by offering integrated ads, complete with measurable and tangible analytics.
- Quality and Global Scale: Enable streaming video to global audiences in a secure environment.
- Security : Configure a variety of security options beyond password protection and geo-blocking, including SSO and integration with user management solutions.
- Expertise and support: Engage with Brightcove’s customer experience team and support organization to meet business objectives.
“Like most B2B companies, we had to quickly pivot from an in-person event to a virtual customer conference when COVID-19 hit. Our strategy was to embrace the remote reality but also to create an experience that felt like a performance and developed a sense of community,“ said Kathie Johnson, Chief Marketing Officer, Talkdesk. “To do this, we selected Brightcove as the platform and leveraged its integration partner Pigeonhole for the live polling and social interaction. One analyst who compared B2B customer conferences stated Opentalk 2020 virtual ‘struck the best balance of event duration, content, and engagement.’ The development process with Brightcove was seamless and the response to our program has been extremely positive.”
“The pandemic is video’s evolutionary moment, and as a result, video is now at the forefront of how we communicate with others, how we conduct business, and is enabling us to stay connected even when physically apart,” said Sara Larsen, Chief Marketing Officer, Brightcove. “Events are a place for information sharing, learning, business building, and networking. Now, more than ever, we need events to flourish and connect us in a virtual video experience. Brightcove Virtual Events Experiences allows organizations to deliver exceptional virtual events quickly and securely, without sacrificing the attendee experience. With this solution, we’re not only helping our customers adapt to the changing landscape but also allowing them to stay connected with their audiences with an engaging, innovative video-driven digital experience.”
For more information on Brightcove Virtual Event Experiences, visit: https://www.brightcove.com/en/solutions/virtual-event
About Brightcove Inc. (NASDAQ: BCOV)
We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.
Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005507/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
